StudyManager Releases Reveal Version 3.1
StudyManager, Inc., a healthcare IT company and creator of StudyManager clinical trial management software (CTMS), today announced the release of Reveal version 3.1, expanding the recruitment, financial, and reporting capabilities of its clinical trial management software (CTMS) for sites and hospitals.
Expanded Business Management and Productivity Tools for Research Sites
Reveal 3.1 allows research organizations to centralize study information, organize research activities, and increase recruitment and financial performance.
Strong Market Response to Reveal and Personalized Service
StudyManager has seen a 40% increase in Reveal sales in the second half of 2010, compared to the first half of the year. Growth is expected to accelerate further in 2011, as StudyManager pairs its Reveal cloud solution with an on-premises option and continues to expand features and services. With Reveal, each customer gets a dedicated trainer who builds a training plan around the customer’s needs and objectives.
Improving the Research Site "Bottom Line"
Reveal is built on the feedback and experience of StudyManager's customers, and the company's nearly 20 years in the field. Then, Reveal's decision support tools can have a big impact on the bottom line, helping sites negotiate more favorable contracts, make enrollment course corrections, and ensure they get paid for all study activity.
Reveal features focus on helping sites centralize study information, and:
- Improve clinical trial recruitment and enrollment results
- Negotiate more favorable contracts
- Ensure payment for all study activity–including items that have been historically difficult for sites to track such as screen-fails, holdbacks, and one-time fees
- Support clinical trial compliance efforts including federal patient privacy regulations, clinical compliance with sponsors’ protocols, and billing compliance to eliminate potential for double-billing of multiple payers
- Develop best practices and automate daily tasks to save time, reduce stress, and cut down on mistakes
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
STEP UP Trial Shows Semaglutide 7.2 mg Achieves Superior Weight Loss vs. 2.4 mg, Placebo
January 17th 2025Semaglutide 7.2 mg significantly outperformed semaglutide 2.4 mg and placebo with a 20.7% average reduction in weight and a comparable safety and tolerability profile, further establishing its efficacy in obesity treatment.
